Mori M - Search Results

1

Broad spectrum and potent antitumor activities of YM155, a novel small-molecule survivin suppressant, in a wide variety of human cancer cell lines and xenograft models.

Nakahara T, Kita A, Yamanaka K, Mori M, Amino N, Takeuchi M, Tominaga F, Kinoyama I, Matsuhisa A, Kudou M, Sasamata M. Nakahara T, et al. Among authors: mori m. Cancer Sci. 2011 Mar;102(3):614-21. doi: 10.1111/j.1349-7006.2010.01834.x. Epub 2011 Jan 12. Cancer Sci. 2011. PMID: 21205082 Free article.

2

YM155, a novel small-molecule survivin suppressant, induces regression of established human hormone-refractory prostate tumor xenografts.

Nakahara T, Kita A, Yamanaka K, Mori M, Amino N, Takeuchi M, Tominaga F, Hatakeyama S, Kinoyama I, Matsuhisa A, Kudoh M, Sasamata M. Nakahara T, et al. Among authors: mori m. Cancer Res. 2007 Sep 1;67(17):8014-21. doi: 10.1158/0008-5472.CAN-07-1343. Cancer Res. 2007. PMID: 17804712

3

YM753, a novel histone deacetylase inhibitor, exhibits antitumor activity with selective, sustained accumulation of acetylated histones in tumors in the WiDr xenograft model.

Shindoh N, Mori M, Terada Y, Oda K, Amino N, Kita A, Taniguchi M, Sohda KY, Nagai K, Sowa Y, Masuoka Y, Orita M, Sasamata M, Matsushime H, Furuichi K, Sakai T. Shindoh N, et al. Among authors: mori m. Int J Oncol. 2008 Mar;32(3):545-55. Int J Oncol. 2008. PMID: 18292931

4

Minodronic acid, a third-generation bisphosphonate, antagonizes purinergic P2X(2/3) receptor function and exerts an analgesic effect in pain models.

Kakimoto S, Nagakura Y, Tamura S, Watabiki T, Shibasaki K, Tanaka S, Mori M, Sasamata M, Okada M. Kakimoto S, et al. Among authors: mori m. Eur J Pharmacol. 2008 Jul 28;589(1-3):98-101. doi: 10.1016/j.ejphar.2008.05.011. Epub 2008 May 20. Eur J Pharmacol. 2008. PMID: 18565509

5

[Pharmacological profile and clinical efficacy of minodronic acid hydrate as a new therapeutic agent for osteoporosis].

Tanaka M, Mori H, Shimizu K, Toshiyuki, Matsuoka, Yamamotoya H, Minamide T, Mori M, Nozaki K, Usui T, Shimokawa K, Suzuki H, Aoyama K, Kimoto A, Sasamata M, Miyata K. Tanaka M, et al. Among authors: mori h, mori m. Nihon Yakurigaku Zasshi. 2009 Sep;134(3):149-57. doi: 10.1254/fpj.134.149. Nihon Yakurigaku Zasshi. 2009. PMID: 19749488 Review. Japanese. No abstract available.

6

Antitumor effects of YM155, a novel survivin suppressant, against human aggressive non-Hodgkin lymphoma.

Kita A, Nakahara T, Yamanaka K, Nakano K, Nakata M, Mori M, Kaneko N, Koutoku H, Izumisawa N, Sasamata M. Kita A, et al. Among authors: mori m. Leuk Res. 2011 Jun;35(6):787-92. doi: 10.1016/j.leukres.2010.11.016. Epub 2011 Jan 14. Leuk Res. 2011. PMID: 21237508

7

Sepantronium bromide (YM155) enhances response of human B-cell non-Hodgkin lymphoma to rituximab.

Kita A, Mitsuoka K, Kaneko N, Nakata M, Yamanaka K, Jitsuoka M, Miyoshi S, Noda A, Mori M, Nakahara T, Sasamata M. Kita A, et al. Among authors: mori m. J Pharmacol Exp Ther. 2012 Oct;343(1):178-83. doi: 10.1124/jpet.112.195925. Epub 2012 Jul 11. J Pharmacol Exp Ther. 2012. PMID: 22787117

8

Combination of YM155, a survivin suppressant with a STAT3 inhibitor: a new strategy to treat diffuse large B-cell lymphoma.

Kaneko N, Kita A, Yamanaka K, Mori M. Kaneko N, et al. Among authors: mori m. Leuk Res. 2013 Sep;37(9):1156-61. doi: 10.1016/j.leukres.2013.05.010. Epub 2013 Jun 6. Leuk Res. 2013. PMID: 23746965

9

The selective anaplastic lymphoma receptor tyrosine kinase inhibitor ASP3026 induces tumor regression and prolongs survival in non-small cell lung cancer model mice.

Mori M, Ueno Y, Konagai S, Fushiki H, Shimada I, Kondoh Y, Saito R, Mori K, Shindou N, Soga T, Sakagami H, Furutani T, Doihara H, Kudoh M, Kuromitsu S. Mori M, et al. Among authors: mori k. Mol Cancer Ther. 2014 Feb;13(2):329-40. doi: 10.1158/1535-7163.MCT-13-0395. Epub 2014 Jan 13. Mol Cancer Ther. 2014. PMID: 24419060

10

Synergistic antitumor activities of sepantronium bromide (YM155), a survivin suppressant, in combination with microtubule-targeting agents in triple-negative breast cancer cells.

Kaneko N, Yamanaka K, Kita A, Tabata K, Akabane T, Mori M. Kaneko N, et al. Among authors: mori m. Biol Pharm Bull. 2013;36(12):1921-7. doi: 10.1248/bpb.b13-00515. Biol Pharm Bull. 2013. PMID: 24432379

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

9,776 results

Search Page